Using a novel cell-based assay to profile transcriptional pathway targeting, we have identified a new functional class of thalidomide analogs with distinct and selective anti-leukemic activity. These agents activate nuclear factor of activated T-cells (NFAT) transcriptional pathways while simultaneously repressing NF-κB via a rapid intracellular amplification of reactive oxygen species (ROS). The elevated ROS is associated with increased intracellular free calcium, rapid dissipation of the mitochondrial membrane potential, disrupted mitochondrial structure and caspase-independent cell death. This cytotoxicity is highly selective for transformed lymphoid cells, reversed by free radical scavengers, synergizes with the anti-leukemic activity or other redox directed compounds, and preferentially targets cells in S-phase of the cell cycle. Live cell imaging reveals a rapid drug-induced burst of reactive oxygen species originating in the endoplasmic reticulum and associated mitochondria just prior to spreading throughout the cell. As members of a novel functional class of "redox reactive" thalidomides, these compounds provide a new tool through which selective cellular properties of redox status and intracellular bioactivation can be leveraged by rational combinatorial therapeutic strategies and appropriate drug design to exploit cell-specific vulnerabilities for maximum drug efficacy.
Introduction
Thalidomide is a synthetic glutamic acid derivative originally marketed as a sedative and anti-emetic in 1954 1, 2 . However, in 1961 it was quickly withdrawn from distribution when its teratogenic properties were discovered 1, 2 . Several years later the serendipitous finding that thalidomide could allay the symptoms of erythema nodosum led to its re-emergence as a treatment for various proinflammatory and autoimmune conditions 3 . Though many of the antiinflammatory properties of thalidomide have been linked to its ability to repress tumor necrosis factor alpha (TNF-α) expression 4 , the mechanisms underlying most of its therapeutic effects, including its ability to co-stimulate T-cells 5 , remained a mystery. In 1994, speculation that thalidomide teratogenicity is linked to the repression of angiogenesis 6 spawned a new wave of clinical investigations that expanded the use of thalidomide for the treatment of various malignancies, including multiple myeloma, melanoma, renal cell carcinoma, and prostate cancer 1, 2 .
The therapeutic promise of thalidomide became a motivation to develop more effective derivatives with reduced toxicity. Several chemical classes of compounds were subsequently developed. One group, referred to as IMiDs™(immunomodulatory drugs) 2 was identified because of its potential to promote T-cell co-stimulatory activity. A second group, referred to as the SelCIDs™ (selective cytokine inhibitory drugs), were found to be potent phosphodiesterase 4 (PDE4) inhibitors 7 . Both groups repress TNF-α
For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From expression. IMiDs are currently in phase II and phase III clinical trials for multiple myeloma, metastatic melanoma and prostate cancer 1, 2 . Though SelCIDs are also effective inhibitors of angiogenesis activity and recent studies indicate that SelCIDs possess significant anti-tumor activity, they have no immunomodulatory properties.
In 1999, it was observed that thalidomide teratogenicity may be due to a speciesspecific conversion to free radical intermediates in embryonic tissue 8 . This observation was complemented by the finding that thalidomide underwent a species-dependent intracellular bioactivation in the endoplasmic reticulum to generate antiangiogenic intermediates containing 5-OH and 5'-OH modifications of pthalimide and glutarimide rings respectively 9 . These 5-OH and 5'-OH intermediates of thalidomide therefore became the structural basis for the design of a third chemical class of thalidomide analogs, represented by N-substituted and tetraflourinated analogs 10 . Like the IMiDs and SelCiDs, this category of drugs also possesses significant anti-tumor activity 10, 11 though the precise mechanism of action is unclear. Thus, despite an extensive history as an important group of therapeutic compounds with promising results in countless clinical and pre-clinical studies, the functional pathways and cellular processes underlying the mechanism of action of thalidomide and its derivatives remain loosely defined.
For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From Recently we developed a high throughput transcriptional assay that profiles transcriptional pathway targeting of various immunomodulatory compounds against an array of extra-cellular stimulatory conditions in human T-cells 12 . This expanded regulatory view provides a more selective and pathway specific means of evaluating the drug-targeted integration of signal transduction events and transcriptional responses. In this study we examined and compared the transcriptional targeting of thalidomide (cc2001); the IMiDs Revlimid (cc5013, lenalidomide) 2 and Actimid (cc4047) 2 ; the SelCiD, Rolipram (cc4001) 13 ; and the thalidomide analogs CPS11, CPS45, and CPS49 11, 14 . By profiling the transcriptional pathway and signal transduction targeting of these "second generation" derivatives and thalidomide we have identified a novel functional class of "redox reactive" thalidomide analogs that act through direct manipulation of cellular redox state to selectively kill leukemic cells.
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METHODS

Cell Culture and High Throughput Transfections
Growth of Jurkat T-cells and high throughput transfection were performed as previously described 12 . Cells were harvested 5 h after treatment. Normalization of luciferase values was performed as previously described 12 .
Phytohaemagglutinin (PHA) (Amersham Biosciences Corp), phorbol 12-myristate 13-acetate (PMA) (Sigma), ionomycin (EMD Biosciences, Inc.), anti-CD3 (OKT3 ascites, ATCC), Actimid (Celgene), Revlimid (Celgene), Thalidomide (Celgene), L-Buthionine-(S,R)-sulfoximine (Sigma) and anti-CD28 monoclonal antibody (Dr.
Carl June, University of Pennsylvania) were added as indicated. The average standard error for all measurements in the entire experiment was less than 15% of the mean with a median of 14% of the mean. All plasmids used in the analysis are previously described 12 . PBMCs were isolated by apheresis from healthy human donors and proliferated by incubation with 1:1000 dilution of anti-CD3 in the presence of IL-2 at 10 U/ml for 5 days in RPMI with 10% fetal calf serum.
Cell viability studies were performed in triplicate in 3 independent studies using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay according to the manufacturers instructions (Roche Applied Sciences).
Cell Cycle Synchronization by Centrifugal Elutriation
Elutriation was performed beginning with ~3-3.5 X 10 8 L1210 cells using a Beckman JE-5.0 elutriation rotor equipped with a standard chamber and eluted with increasing flow rates (20 to 35 ml/min) at constant rotor speed (2000 rpm)
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Antibodies and Immunoblot Analysis
Antibodies used were specific for: Iκ-Bα, phospho-IκBα (Ser32), RelA(p65) and phospho-RelA (Ser536) (Cell Signaling Technology Inc.), PARP, Caspase 7, and Caspase 3 (BD Biosciences). Whole cell lysates were prepared in buffers containing: 50 mM Hepes, 20 mM sodium pyrophosphate, 25 mM β-glycerophosphate, 50 mM sodium fluoride, 5 mM sodium molybdate, 5 mM EDTA, 150 mM orthophenanthroline, 1% NP-40, 0.5% deoxycholate, 1% Triton X-100, Mammalian Protease Inhibitor (MPI)(Sigma) and 0.2 mM Na 2 V0 4 .
Nuclear and cytosolic fractions were prepared by modification of a previously described procedure 16 . 10 to 30 µg of the fractions were used for immunoblot analysis.
Cytokine Measurements
Cytokine measurements were made on triplicate independent cell supernatants using Meso Scale Discovery (MSD) Multi-Spot TM plates and an MSD Sector Imager 6000 reader (Meso Scale Discovery) as previously described 12 .
Ten cytokines were measured simultaneously in each well of 96 well plates using MSD's 10-Plex Human Cytokine Panel (GM-CSF, IL1β, IL2, IL4, IL5, IL6, IL8, IL10, IL12p70, TNFα) according to the manufacturer's instructions. 
ROS Determinations
Reactive oxygen species (ROS) generation was determined by the increase in DCFDA fluorescence 17 
Electron Microscopy
Cell pellets were fixed in 2.5% glutaraldehyde, postfixed in 0.5% osmium tetroxide dehydrated, and embedded in Spurs epoxy resin. Ultrathin sections (90 nm) were made and double-stained with uranyl acetate and lead citrate, and viewed with a Philips CM10 transmission electron microscope (Phillips Electronics, Mahway, NJ).
Statistical analysis
Principal component analysis was performed using Partek Pro 5.1 (Partek, St. 
Louis, MO
Specific trends in thalidomide analog transcriptional pathway targeting reveal a novel functional class
To objectively discern regulatory trends or patterns common to any of the seven compounds, we employed the method of principal component analysis (PCA) 12 .
PCA is a computational technique used to analyze data with multiple variables or "dimensions". This is accomplished by a mathematical transformation that reduces the 96 variables (shown in Figure 1B ) to a smaller number of composite independent variables that capture most of the characteristics of the data set 12, 19 . This reduction in variables or "dimensions" simplifies the analysis graphically and allows for trends in the data to be more easily appreciated. In Figure 1D . The majority of the variance within the data set (i.e. its characteristics) is captured in the first three PCs.
CPS11, CPS45 and CPS49 preferentially induce NFAT transcriptional pathways while simultaneously inhibiting NF-kappa B activity
One readily apparent trend in the PCA shown in Figure 1C is the clear separation of CPS11, CPS45, and CPS49 from the other thalidomide compounds along PC1. This indicates these compounds share one or more characteristics defined by the composition of PC1 that distinguishes them from the others. To determine relevant contributions to the composition of PC1, we examined its eigenvector coefficients 12 . A profile of the magnitude of the PC1 eigenvector coefficients reveals a strong contribution from both NF-κB and NFAT derived variables ( Figure 2A ). Notably the NFAT and NF-κB contributions are anticorrelated indicating that one of these pathways is activated while the other is repressed. Re-examination of the hierarchical clustering in Figure 1B confirms these trends. The CPS compounds induce NFAT transcription pathways while repressing NF-κB pathways.
An alternate PCA approach to determine the factors that distinguish CPS11, CPS45, and CPS49 as a group is shown in Figure 2B . Each mitogen combination is evaluated using a 6 x 8 matrix Figure 3C ). Hierarchical clustering analysis of the proteomic profiles reveals the unexpected finding that the CPS class has a general tendency to repress rather than stimulate inflammatory cytokine secretion ( Figure 3D ). In contrast, thalidomide showed substantial induction of IL2 expression as has been reported previously 5, 23 .
CPS45 and CPS49 elevate intracellular ROS
The inability of the CPS-induced NFAT pathways to stimulated cytokine production suggested that this process may represent an atypical activation of NFAT. Reactive oxygen species (ROS) have been shown to activate NFAT by mobilization of intracellular calcium secondary to ER stress 24, 25 . Such elevated ROS could antagonize cytokine gene expression. We therefore measured the ability of thalidomide and the CPS drugs to increase intracellular ROS using the 17 . Cells treated 30 min with CPS45 or CPS49 generated significant levels of ROS. In contrast, thalidomide showed no difference and CPS11 showed only minimal elevation compared to untreated cells ( Figure 3E) .
Notably, the ability of the four drugs to generate reactive oxygen species was directly proportional to their capacity to stimulate NFAT. Significant levels of ROS are routinely generated during mitogen stimulation of T-cells 17, 26 .
Therefore the generation of ROS by CPS45 was compared in both resting and PHA/PMA stimulated T-cells ( Figure 3F ). The addition of CPS45 results in a dramatic increase in ROS in PHA/PMA stimulated T-cells indicating that CPS45 readily amplifies ROS levels generated from intracellular sources.
CPS45 induces a rapid ROS-mediated caspase-independent cell death
The effects of ROS on cellular homeostasis are complex. Low levels can promote protein phosphorylation, mobilize calcium stores, and activate transcription factors [27] [28] [29] . At higher concentration it can damage membranes, inhibit caspases and other enzymes and promote a necrotic cell death 
Selective Killing of Transformed Leukemic cells by CPS45
The levels of ROS are much higher in transformed and/or malignant cells when compared to normal cells due to their higher metabolic status 31 . Since CPS45 amplifies the elevation of ROS in mitogen stimulated Jurkat cells ( Figure 3F To explore the selectivity of the CPS drugs more thoroughly, the viability of 15 different transformed human cell lines (Supplemental Table 1 ) was compared to resting and proliferating primary human PBMCs (mitogen-induced PBMC blasts) after 16 h treatment with increasing concentrations of CPS45 ( Figure 5C 
Pharmacologic manipulation of cellular redox state influences sensitivity to cell killing by redox-reactive thalidomide compounds
The redox state of the cell is a balance between ROS production and removal by enzymatic conversion or buffering by endogenous molecular anti-oxidants.
Glutathione (GSH) is the major intracellular buffer for ROS. L-Buthionine-(S,R)-sulfoximine (BSO) depletes intracellular glutathione through inhibition of γ-
glutamylcysteine synthetase, an enzyme required for GSH synthesis 32 . As shown in Figure 5D , 24h preincubation with BSO significantly increases the sensitivity of HeLa cells to CPS45.
CPS45 synergizes with the anti-leukemic activity of parthenolide
Parthenolide (PTL) is a sesquiterpene lactone derived from the Mexican Indian plant European feverfew (Tanacetium parthenium) that exhibits anti-inflammatory and anti-leukemic activity through a mechanism linked to increased ROS and inhibition of NF-κB activity 33 . These similarities suggest that the combination of PTL and CPS45 might by synergistic. This prediction was tested by dose response curves and median dose effect analysis 18 of cell viability following
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At all doses tested co-administration of CPS45 and PTL yielded combination indexes (CI) that were considerably less than one, indicating clear a synergy between CPS45 and PTL.
CPS45 shows preferential cytotoxicity against cells in S-phase
The mechanism by which ROS regulates cell cycle is not clear. However ROS is known to play an important role in growth factor stimulated progression from G1 to S phase, and decreases in ROS are associated with impaired G1 to S transition 34, 35 . Thus it is likely that the elevation of ROS required for cells in Sphase may increase their vulnerability to redox-reactive thalidomides. To answer this question the mouse L1210 cells were used since they are easily synchronized by centrifugal elutriation without the confounding cellular stress of mitotic poisons or anti-metabolic drugs. As shown in Figure 6A , L1210 cells are sensitive to CPS45 in contrast to thalidomide. Moreover, like Jurkat and in contrast to HeLa, treatment of L1210 with CPS45 causes significant elevation of intracellular ROS while thalidomide at 20-fold higher concentration has no effect ( Figure 6B ). As anticipated, treatment of L1210 cells synchronized in G1, S and G2 shows increased cytotoxicity in S phase ( Figure 6C ). This observation also explains the previously observed increased sensitivity of PMBC blast to CPS45 treatment ( Figure 5C ). 
DISCUSSION
In this study we profiled seven different thalidomide-related compounds based on their transcriptional pathway targeting in response to multiple T-cell mitogens.
Though we found that thalidomide and its analogs have very pleiotropic influences, a regulatory signature was identified that defines a new functional class of "redox-reactive" thalidomide analogs uniquely characterized by their ability to upregulate NFAT transcriptional pathways through the amplification of intracellular ROS. A schematic of the proposed sequence of events is shown in Figure 7C .
Oxidative stress plays a well recognized role in mediating multiple forms of cell death in a variety of tissues 26, 36 . The contribution of ROS to the mechanism of chemotherapeutic cytotoxicity was recognized as early as 40 years ago, however its manipulation as a treatment paradigm in cancer has only recently emerged as a promising new strategy 37,38 39 . Cellular ROS is a dynamic state defined by the equilibrium between the cell's internal generation of ROS and its antioxidant system 36 . These properties determine the selective nature of its influence on individual cells and cell types. Malignant cells tend to have higher basal levels of ROS due to higher metabolic rates associated with multiple activated oncogenic pathways and the increased likelihood of mitochondrial dysfunction 31, 37 .
Mitochondrial genes have a higher frequency of mutation due to their lack of histones , introns and a limited DNA repair capacity 37 .
to mitochondrial dysfunction can be exploited by redox-targeting therapeutic strategies.
Leukemias have a higher susceptibility to elevated ROS often enhanced following chemotherapy, possibly secondary to accrued mitochondrial DNA damage [40] [41] [42] [43] . This is consistent with reports that cells obtained from chronic lymphocytic leukemia patients refractory to chemotherapy show higher levels of ROS and are more sensitive to cytotoxic compounds that elevate ROS 42 . The in vitro anti-leukemic activity of the redox-reactive thalidomides indicates that this class of compounds may be effective against CLL and other leukemias.
Though the inhibition of NF-κB is a common feature of most thalidomide analogues, prior studies have shown that this activity is highly dependent on the mode of stimulation. In fact, earlier observations in Jurkat have shown that PMA activated NF-κB is resistant to thalidomide 44 . Moreover, hydrogen peroxide activated NF-κB is paradoxically induced rather than inhibited by thalidomide 44 .
The ability to rapidly and directly amplify endogenous ROS levels is a property unique to the redox-reactive thalidomides. Like PTL, the repression of NF-κB pathways by CPS45 suggests a role for this pathway in its anti-leukemic activity and is also likely to partially explain the observed repression of inflammatory cytokine secretion ( Figure 3D ). While loss of mitochondrial stability secondary to NF-κB repression undoubtedly contributes to its cytotoxicity, the rapid kinetics of CPS45 mediated mitochondrial destabilization and ROS amplification suggest
influences that are less dependent on transcription. In this regard, it is important to note that a dose-dependent dual targeting of NF-κB and ROS by PTL has been recently proposed to occur in leukemic cells 45 . Future analysis of the kinetics of this CPS45/PTL similarity and its dose-dependence is certain to provide further insights into the mechanism of action of the redox-reactive thalidomides.
The synergy between the redox-reactive thalidomides and PTL suggests that a similar combinatorial potential may be elicited by co-administration with other chemotherapeutic compounds that utilize ROS in cytotoxic pathways. Known candidates with selective anti-leukemic activity include: arsenic trioxide 46 , Bortezomib 47 , DNA alkylating agents 48 , ceramide 49 and CD47 ligation 50 , BSO 51 , rituximab 52 , motexafin gadolinium (MGd) 53 , and 2-Methoxyestradiol (2-ME) 42 .
Prior reports had identified a role for free radicals in the action of the parent compound thalidomide, but this property is indirect and requires multiple speciesspecific bioactivation steps 8 . As with other compounds capable of generating free radicals there are many aspects of the spectrum of action of redox-reactive thalidomides that remain to be determined. Bone marrow suppression and nephrotoxicity will have to be explored. In initial animal studies, high levels of CPS11 and CPS49 were well tolerated and CPS45 showed no toxicity at all
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Over seventy years ago Otto Warburg noted that cancer-transformed cells displayed an altered metabolism characterized by a shift in energy production from mitochondrial-mediated oxidative phosphorylation to glycolysis in the cytoplasm 54 . Although years later it is still debated as to whether this shift is causative or a result of cancer, this change in cellular state represents a major vulnerability that can be therapeutically exploited. The precise components of the organelles that are rapidly targeted by the redox-reactive thalidomides to amplify ROS levels are currently under investigation and are likely to involve multiple components of the cytochrome P-450 system in addition to other ER and mitochondrial constituents 55 . Given the high degree of genetic variation in components of these systems many effects of the redox-reactive thalidomides are likely to reflect population-specific differences and biochemistries that will require further exploration. 
